Skip to main content
SpringerLink
Log in

Genetic Factors Underlying Treatment Resistance in Psychiatry

  • Chapter
  • First Online:
Book cover Treatment Resistance in Psychiatry

  • 1169 Accesses

Abstract

However, there is strong belief that further search for genetic factors underlying treatment response, which are also defined as “treatment biomarkers,” would contribute to the personalized medicine approach, in which biomarkers would guide decision-making and help to select the most suitable medication for individual patients. Moreover, incorporation of genetic factors into treatment algorithms could speed recovery from disease by shortening or eliminating lengthy and ineffective trials and thus reduce the risk of treatment resistance. In this chapter, we review the current state of pharmacogenomics of several mental health disorders including latest results from candidate genes and genome-wide association studies. Although a host of genes has been explored in psychiatry, only small numbers of replicated findings have emerged so far. The sample sizes and heterogeneous phenotype definition may be considered the major impediments to success in this important field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aberg K, Adkins DE, Liu Y, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012;12:165–72.

    Article  CAS  PubMed  Google Scholar 

  2. Adams DH, Close S, Farmen M, et al. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately Caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2008;23:267–74.

    Article  CAS  PubMed  Google Scholar 

  3. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry. 2011;16:321–32.

    Article  CAS  PubMed  Google Scholar 

  4. Adli M, Hollinde DL, Stamm T, et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta −50T/C single nucleotide polymorphism. Biol Psychiatry. 2007;62:1295–302.

    Article  CAS  PubMed  Google Scholar 

  5. Alkelai A, Greenbaum L, Rigbi A, et al. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology. 2009;206:491–9.

    Article  CAS  PubMed  Google Scholar 

  6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, vol. 716. 5th ed. Arlington: American Psychiatric Association; 2013.

    Book  Google Scholar 

  7. Andersson E, Rück C, Lavebratt C, et al. Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder. PLoS One. 2013;8:e79015.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Andre K, Kampman O, Illi A, et al. SERT and NET polymorphisms, temperament and antidepressant response. Nord J Psychiatry. 2015;69:531–8.

    Article  PubMed  Google Scholar 

  9. Anton RF, Oroszi G, O’Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65:135–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Anttila S, Illi A, Kampman O, et al. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm. 2005;112:885–90.

    Article  CAS  PubMed  Google Scholar 

  11. Anttila S, Kampman O, Illi A, et al. Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry. 2007;7:22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Arcos-Burgos M, Jain M, Acosta MT, et al. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Mol Psychiatry. 2010;15:1053–66.

    Article  CAS  PubMed  Google Scholar 

  13. Arias AJ, Armeli S, Gelernter J, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008;32:1159–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Arias AJ, Gelernter J, Gueorguieva R, et al. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. Am J Addict. 2014;23:288–93.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 1995a;346:281–2.

    Article  CAS  PubMed  Google Scholar 

  16. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 1996;217:177–8.

    Article  CAS  PubMed  Google Scholar 

  17. Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol. 1995b;39:417–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12:707–47.

    Article  CAS  PubMed  Google Scholar 

  19. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull. 2008;34:1130–44.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355:1615–6.

    Article  CAS  PubMed  Google Scholar 

  21. Arranz MJ, Munro J, Owen MJ, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry. 1998a;3:61–6.

    Article  CAS  PubMed  Google Scholar 

  22. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998b;32:93–9.

    Article  CAS  PubMed  Google Scholar 

  23. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs. 2011;25:933–69.

    Article  CAS  PubMed  Google Scholar 

  24. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;7:405–11.

    Article  CAS  PubMed  Google Scholar 

  25. Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:323–31.

    Article  CAS  PubMed  Google Scholar 

  26. Basu A, Chadda RK, Sood M, et al. Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: a preliminary study. Indian J Med Res. 2015;142:40–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord. 2012;14(Suppl 2):37–50.

    Article  PubMed  Google Scholar 

  28. Baune BT, Dannlowski U, Domschke K, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry. 2010;67:543–9.

    Article  CAS  PubMed  Google Scholar 

  29. Benedetti F, Serretti A, Pontiggia A, et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett. 2005;376:51–5.

    Article  CAS  PubMed  Google Scholar 

  30. Berlin I, Covey LS, Jiang H, Hamer D. Lack of effect of D2 dopamine receptor TaqI A polymorphism on smoking cessation. Nicotine Tob Res. 2005;7:725–8.

    Article  CAS  PubMed  Google Scholar 

  31. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry. 2004;161:1798–805.

    Article  PubMed  Google Scholar 

  32. Biernacka JM, McElroy SL, Crow S, et al. Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J Affect Disord. 2012;136:e21–9.

    Article  CAS  PubMed  Google Scholar 

  33. Binder EB, Owens MJ, Liu W, et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry. 2010;67:369–79.

    Article  CAS  PubMed  Google Scholar 

  34. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36:1319–25.

    Article  CAS  PubMed  Google Scholar 

  35. Bishop JR, Ellingrod VL, Moline J, Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res. 2005;77:253–60.

    Article  PubMed  Google Scholar 

  36. Bolonna AA, Arranz MJ, Munro J, et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett. 2000;280:65–8.

    Article  CAS  PubMed  Google Scholar 

  37. Bolonna AA, Kerwin RW, Munro J, et al. Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr Res. 2001;47:99–103.

    Article  CAS  PubMed  Google Scholar 

  38. Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016;21:1643.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Bousman CA, Sarris J, Won E-S, et al. Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism. J Clin Psychopharmacol. 2014;34:645–8.

    Article  CAS  PubMed  Google Scholar 

  40. Bowers K, Lin P-I, Erickson C. Pharmacogenomic medicine in autism: challenges and opportunities. Paediatr Drugs. 2015;17:115–24.

    Article  PubMed  Google Scholar 

  41. Bozina N, Kuzman MR, Medved V, et al. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res. 2008;42:89–97.

    Article  PubMed  Google Scholar 

  42. Bozina N, Medved V, Kuzman MR, et al. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol (Oxford). 2007;21:728–34.

    Article  CAS  Google Scholar 

  43. Brandl EJ, Tiwari AK, Zhou X, et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J. 2014;14:176–81.

    Article  CAS  PubMed  Google Scholar 

  44. Breitling LP, Twardella D, Hoffmann MM, et al. Prospective association of dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics. 2010;11:527–36.

    Article  CAS  PubMed  Google Scholar 

  45. Bremer T, Diamond C, McKinney R, et al. The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol Diagn Ther. 2007;11:161–70.

    Article  CAS  PubMed  Google Scholar 

  46. Brent D, Melhem N, Ferrell R, et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry. 2010;167:190–7.

    Article  PubMed  Google Scholar 

  47. Brockmöller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72:438–52.

    Article  PubMed  CAS  Google Scholar 

  48. Bruxel EM, Akutagava-Martins GC, Salatino-Oliveira A, et al. ADHD pharmacogenetics across the life cycle: new findings and perspectives. Am J Med Genet B Neuropsychiatr Genet. 2014;165B:263–82.

    Article  PubMed  CAS  Google Scholar 

  49. Bryant RA, Felmingham KL, Falconer EM, et al. Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder. Biol Psychiatry. 2010;67:1217–9.

    Article  CAS  PubMed  Google Scholar 

  50. Cacabelos R. Pharmacogenetic basis for therapeutic optimization in Alzheimer’s disease. Mol Diagn Ther. 2007a;11:385–405.

    Article  CAS  PubMed  Google Scholar 

  51. Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods Find Exp Clin Pharmacol. 2007b;29(Suppl A):1–91.

    CAS  PubMed  Google Scholar 

  52. Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci. 2008a;258(Suppl 1):28–47.

    Article  PubMed  Google Scholar 

  53. Cacabelos R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev Mol Diagn. 2009;9:567–611.

    Article  CAS  PubMed  Google Scholar 

  54. Cacabelos R. Pharmacogenomics in Alzheimer’s disease. Methods Mol Biol. 2008b;448:213–357.

    Article  CAS  PubMed  Google Scholar 

  55. Cacabelos R, Fernandez-Novoa L, Lombardi V, et al. Molecular genetics of Alzheimer’s disease and aging. Methods Find Exp Clin Pharmacol. 2005;27(Suppl A):1–573.

    PubMed  Google Scholar 

  56. Cacabelos R, Llovo R, Fraile C, Fernández-Novoa L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Curr Alzheimer Res. 2007;4:479–500.

    Article  CAS  PubMed  Google Scholar 

  57. Calati R, Crisafulli C, Balestri M, et al. Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;44:271–8.

    Article  CAS  Google Scholar 

  58. Campos-de-Sousa S, Guindalini C, Tondo L, et al. Nuclear receptor rev-erb-{alpha} circadian gene variants and lithium carbonate prophylaxis in bipolar affective disorder. J Biol Rhythm. 2010;25:132–7.

    Article  CAS  Google Scholar 

  59. Chagnon YC, Mérette C, Bouchard RH, et al. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry. 2004;9:1067–74.

    Article  CAS  PubMed  Google Scholar 

  60. Chamorro A-J, Marcos M, Mirón-Canelo J-A, et al. Association of μ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012;17:505–12.

    Article  CAS  PubMed  Google Scholar 

  61. Chang HS, Lee H-Y, Cha J-H, et al. Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34:446–54.

    Article  CAS  PubMed  Google Scholar 

  62. Chang HS, Won E, Lee H-Y, et al. Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants. Behav Brain Res. 2015;292:116–24.

    Article  CAS  PubMed  Google Scholar 

  63. Chen AC, Morgenstern J, Davis CM, et al. Variation in mu-opioid receptor gene (OPRM1) as a moderator of naltrexone treatment to reduce heavy drinking in a high functioning cohort. J Alcohol Drug Depend. 2013;1:101.

    PubMed  Google Scholar 

  64. Chen C-H, Lee C-S, Lee M-TM, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med. 2014;370:119–28.

    Article  CAS  PubMed  Google Scholar 

  65. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75:807–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Chen S-F, Shen Y-C, Chen C-H. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33:470–4.

    Article  CAS  Google Scholar 

  67. Cheon K-A, Jun J-Y, Cho D-Y. Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder. Int Clin Psychopharmacol. 2008;23:291–8.

    Article  PubMed  Google Scholar 

  68. Chianella C, Gragnaniello D, Maisano Delser P, et al. BCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol. 2011;67:1147–57.

    Article  CAS  PubMed  Google Scholar 

  69. Chiesa A, Crisafulli C, Porcelli S, et al. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. Eur Arch Psychiatry Clin Neurosci. 2012;262:305–11.

    Article  PubMed  Google Scholar 

  70. Cinciripini P, Wetter D, Tomlinson G, et al. The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res. 2004;6:229–39.

    Article  CAS  PubMed  Google Scholar 

  71. Clarke TK, Crist RC, Ang A, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J. 2014;14:303–8.

    Article  CAS  PubMed  Google Scholar 

  72. Colle R, Gressier F, Verstuyft C, et al. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J Affect Disord. 2015;175:233–40.

    Article  CAS  PubMed  Google Scholar 

  73. Consortium on Lithium Genetics, Hou L, Heilbronner U, et al. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med. 2014;370:1857–9.

    Google Scholar 

  74. Contini V, Victor MM, Bertuzzi GP, et al. No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD. J Clin Psychopharmacol. 2012;32:820–3.

    Article  CAS  PubMed  Google Scholar 

  75. Contini V, Victor MM, Cerqueira CCS, et al. Adrenergic α2A receptor gene is not associated with methylphenidate response in adults with ADHD. Eur Arch Psychiatry Clin Neurosci. 2011;261:205–11.

    Article  PubMed  Google Scholar 

  76. Contini V, Victor MM, Marques FZC, et al. Response to methylphenidate is not influenced by DAT1 polymorphisms in a sample of Brazilian adult patients with ADHD. J Neural Transm. 2010;117:269–76.

    Article  CAS  PubMed  Google Scholar 

  77. Cooper AJ, Rickels K, Lohoff FW. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. Hum Psychopharmacol. 2013;28:258–62.

    Article  CAS  PubMed  Google Scholar 

  78. Correia CT, Almeida JP, Santos PE, et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010;10:418–30.

    Article  CAS  PubMed  Google Scholar 

  79. Crettol S, Besson J, Croquette-Krokar M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1722–7.

    Article  CAS  Google Scholar 

  80. Crist RC, Clarke T-K, Ang A, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 2013;38:2003–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Cruceanu C, Alda M, Turecki G. Lithium: a key to the genetics of bipolar disorder. Genome Med. 2009;1:79.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. da Silva TL, Pianca TG, Roman T, et al. Adrenergic alpha2A receptor gene and response to methylphenidate in attentiondeficit/hyperactivity disorder-predominantly inattentive type. J Neural Transm. 2008;115:341–5.

    Article  PubMed  CAS  Google Scholar 

  83. Dahl JP, Jepson C, Levenson R, et al. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J. 2006;6:194–9.

    Article  CAS  PubMed  Google Scholar 

  84. Daray FM, Thommi SB, Ghaemi SN. The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord. 2010;12:702–6.

    Article  PubMed  Google Scholar 

  85. David SP, Strong DR, Munafò MR, et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res. 2007;9:1251–7.

    Article  CAS  PubMed  Google Scholar 

  86. De Ruyck K, Nackaerts K, Beels L, et al. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics. 2010;11:1053–63.

    Article  PubMed  Google Scholar 

  87. Del Zompo M, Ardau R, Palmas MA, et al. Lithium response: association study with two candidate genes. Mol Psychiatry. 1999;4:S66–7.

    Article  Google Scholar 

  88. Dimitrova A, Milanova V, Krastev S, et al. Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment. Pharmacogenomics J. 2005;5:35–41.

    Article  CAS  PubMed  Google Scholar 

  89. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, et al. Association studies of 5-HT2A and 5-HT2C serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacol Rep. 2005;57:761–5.

    CAS  PubMed  Google Scholar 

  90. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics. 2008;9:1595–603.

    Article  CAS  PubMed  Google Scholar 

  91. Dogan O, Yuksel N, Ergun MA, et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test. 2008;12:225–31.

    Article  CAS  PubMed  Google Scholar 

  92. Du J, Zhang A, Wang L, et al. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol (Oxford). 2010;24:1115–20.

    Article  CAS  Google Scholar 

  93. Eap CB, Bender S, Jaquenoud Sirot E, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004;24:214–9.

    Article  CAS  PubMed  Google Scholar 

  94. Ellsworth KA, Moon I, Eckloff BW, et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics. 2013;23:156–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Ewald H, Wang AG, Vang M, et al. A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands. Psychiatr Genet. 1999;9:23–34.

    Article  CAS  PubMed  Google Scholar 

  96. Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS. Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association. NeuroMolecular Med. 2011;13:66–76.

    Article  CAS  PubMed  Google Scholar 

  97. Felmingham KL, Dobson-Stone C, Schofield PR, et al. The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol Psychiatry. 2013;73:1059–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Fijal BA, Kinon BJ, Kapur S, et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J. 2009;9:311–8.

    Article  CAS  PubMed  Google Scholar 

  99. Fonseca F, Gratacòs M, Escaramís G, et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther. 2010;14:171–8.

    Article  CAS  PubMed  Google Scholar 

  100. Froehlich TE, Epstein JN, Nick TG, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:1129–39.e2.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Frye MA, McElroy SL, Prieto ML, et al. Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania. J Clin Psychiatry. 2015;76:174–80.

    Article  PubMed  Google Scholar 

  102. Ftouhi-Paquin N, Alda M, Grof P, et al. Identification of three polymorphisms in the translated region of PLC-gamma1 and their investigation in lithium responsive bipolar disorder. Am J Med Genet. 2001;105:301–5.

    Article  CAS  PubMed  Google Scholar 

  103. GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170:207–17.

    Article  Google Scholar 

  104. Geschwind DH. Advances in autism. Annu Rev Med. 2009;60:367–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Goldberger C, Gourion D, Leroy S, et al. Population-based and family-based association study of 5’UTR polymorphism of the reelin gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2005;137B:51–5.

    Article  PubMed  Google Scholar 

  106. Gu B, Wang L, Zhang A-P, et al. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics. 2008;18:721–7.

    Article  CAS  PubMed  Google Scholar 

  107. Gupta M, Bhatnagar P, Grover S, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics. 2009;10:385–97.

    Article  CAS  PubMed  Google Scholar 

  108. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158:1568–78.

    Article  CAS  PubMed  Google Scholar 

  109. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127–34. https://doi.org/10.1002/cpt.147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93:402–8. https://doi.org/10.1038/clpt.2013.2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235. https://doi.org/10.1055/s-0031-1286287.

    Article  PubMed  Google Scholar 

  112. Hoekstra PJ, Troost PW, Lahuis BE, et al. Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. J Child Adolesc Psychopharmacol. 2010;20:473–7. https://doi.org/10.1089/cap.2009.0071.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Horstmann S, Lucae S, Menke A, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35:727–40. https://doi.org/10.1038/npp.2009.180.

    Article  CAS  PubMed  Google Scholar 

  114. Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387:1085–93. https://doi.org/10.1016/S0140-6736(16)00143-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Houston JP, Adams DH, Kirkwood SC, et al. Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia. J Clin Psychopharmacol. 2007;27:520–3. https://doi.org/10.1097/JCP.0b013e31814f4d82.

    Article  PubMed  Google Scholar 

  116. Hu Q, Zhang S-Y, Liu F, et al. Influence of GNB3 C825T polymorphism on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2015;172:103–9. https://doi.org/10.1016/j.jad.2014.09.039.

    Article  CAS  PubMed  Google Scholar 

  117. Hwang R, Shinkai T, De Luca V, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 2005;181:179–87. https://doi.org/10.1007/s00213-005-2223-5.

    Article  CAS  PubMed  Google Scholar 

  118. Hwang R, Shinkai T, De Luca V, et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol (Oxford). 2007;21:718–27. https://doi.org/10.1177/0269881106072341.

    Article  CAS  Google Scholar 

  119. Hwang R, Shinkai T, Deluca V, et al. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol. 2006;16:248–59. https://doi.org/10.1016/j.euroneuro.2005.09.004.

    Article  CAS  PubMed  Google Scholar 

  120. Hwang R, Zai C, Tiwari A, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010;10:200–18. https://doi.org/10.1038/tpj.2009.65.

    Article  CAS  PubMed  Google Scholar 

  121. Ikeda M, Tomita Y, Mouri A, et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry. 2010;67:263–9. https://doi.org/10.1016/j.biopsych.2009.08.030.

    Article  CAS  PubMed  Google Scholar 

  122. Ikeda M, Yamanouchi Y, Kinoshita Y, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. 2008;9:1437–43. https://doi.org/10.2217/14622416.9.10.1437.

    Article  CAS  PubMed  Google Scholar 

  123. Illi A, Setälä-Soikkeli E, Viikki M, et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport. 2009;20:1125–8. https://doi.org/10.1097/WNR.0b013e32832eb708.

    Article  CAS  PubMed  Google Scholar 

  124. Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics. 2008;18:317–23. https://doi.org/10.1097/FPC.0b013e3282f70492.

    Article  CAS  PubMed  Google Scholar 

  125. Ito K, Yoshida K, Sato K, et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res. 2002;111:235–9.

    Article  CAS  PubMed  Google Scholar 

  126. Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011;168:265–75.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Johnson BA, Seneviratne C, Wang X-Q, et al. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry. 2013;170:1020–31.

    Article  PubMed  Google Scholar 

  128. Jones JD, Comer SD. A review of pharmacogenetic studies of substance-related disorders. Drug Alcohol Depend. 2015;152:1–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Joober R, Benkelfat C, Brisebois K, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci. 1999;24:141–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  130. Joober R, Grizenko N, Sengupta S, et al. Dopamine transporter 3′-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology. 2007;32:1370–6.

    Article  CAS  PubMed  Google Scholar 

  131. Joober R, Rouleau GA, Lal S, et al. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res. 2005;77:35–41.

    Article  PubMed  Google Scholar 

  132. Joyce PR, Mulder RT, Luty SE, et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003;6:339–46.

    Article  CAS  PubMed  Google Scholar 

  133. Kakiuchi C, Kato T. Lithium response and -116C/G polymorphism of XBP1 in Japanese patients with bipolar disorder. Int J Neuropsychopharmacol. 2005;8:631–2.

    Article  CAS  PubMed  Google Scholar 

  134. Kambeitz J, Romanos M, Ettinger U. Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Pharmacogenomics J. 2014;14:77–84.

    Article  CAS  PubMed  Google Scholar 

  135. Kampman O, Illi A, Hänninen K, et al. RGS4 genotype is not associated with antipsychotic medication response in schizophrenia. J Neural Transm. 2006;113:1563–8.

    Article  CAS  PubMed  Google Scholar 

  136. Kang R-H, Hahn S-W, Choi M-J, Lee M-S. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology. 2007;56:1–5.

    Article  CAS  PubMed  Google Scholar 

  137. Karpyak VM, Biernacka JM, Geske JR, et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry. 2014;4:e462.

    Article  CAS  PubMed  Google Scholar 

  138. Kato M, Fukuda T, Wakeno M, et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:115–23.

    Article  CAS  PubMed  Google Scholar 

  139. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15:473–500.

    Article  CAS  PubMed  Google Scholar 

  140. Kato M, Wakeno M, Okugawa G, et al. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1041–4.

    Article  CAS  Google Scholar 

  141. Kautzky A, Baldinger P, Souery D, et al. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. Eur Neuropsychopharmacol. 2015;25:441–53.

    Article  CAS  PubMed  Google Scholar 

  142. Kawaguchi DM, Glatt SJ. GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis. Pharmacogenomics. 2014;15:1451–9.

    Article  CAS  PubMed  Google Scholar 

  143. Keers R, Bonvicini C, Scassellati C, et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol (Oxford). 2011;25:867–74.

    Article  CAS  Google Scholar 

  144. Kereszturi E, Tarnok Z, Bognar E, et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1431–5.

    Article  CAS  PubMed  Google Scholar 

  145. Kim B, Choi EY, Kim CY, et al. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol. 2008;23:61–7.

    Article  CAS  PubMed  Google Scholar 

  146. Kim B, Kim CY, Lee MJ, Joo YH. Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res. 2009a;168:209–12.

    Article  CAS  PubMed  Google Scholar 

  147. Kim B-N, Cummins TDR, Kim J-W, et al. Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children. Int J Neuropsychopharmacol. 2011;14:1399–410.

    Article  CAS  PubMed  Google Scholar 

  148. Kim B-N, Kim J-W, Hong SB, et al. Possible association of norepinephrine transporter −3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Behav Brain Funct. 2010;6:57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Kim H, Lim S-W, Kim S, et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA. 2006;296:1609–18.

    Article  CAS  PubMed  Google Scholar 

  150. Kim S-G, Kim C-M, Choi S-W, et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology. 2009b;201:611–8.

    Article  CAS  PubMed  Google Scholar 

  151. Kim Y-G, Chang H-S, Won E-S, et al. Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in Korean patients with major depression. Neuropsychobiology. 2014;69:210–9.

    Article  CAS  PubMed  Google Scholar 

  152. Kirchheiner J, Lorch R, Lebedeva E, et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics. 2008;9:841–6.

    Article  CAS  PubMed  Google Scholar 

  153. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442–73.

    Article  CAS  PubMed  Google Scholar 

  154. Kirley A, Lowe N, Hawi Z, et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet. 2003;121B:50–4.

    Article  PubMed  Google Scholar 

  155. Kishi T, Yoshimura R, Kitajima T, et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. NeuroMolecular Med. 2010;12:237–42.

    Article  CAS  PubMed  Google Scholar 

  156. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93:8455–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Kohlrausch FB, Salatino-Oliveira A, Gama CS, et al. Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res. 2010;44:1158–62.

    Article  PubMed  Google Scholar 

  158. Kohlrausch FB, Salatino-Oliveira A, Gama CS, et al. G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics. 2008;9:1429–36.

    Article  CAS  PubMed  Google Scholar 

  159. Kooij JS, Boonstra AM, Vermeulen SH, et al. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am J Med Genet B Neuropsychiatr Genet. 2008;147B:201–8.

    Article  PubMed  CAS  Google Scholar 

  160. Kosten TR, Wu G, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β -hydroxylase. Biol Psychiatry. 2013;73:219–24.

    Article  CAS  PubMed  Google Scholar 

  161. Kranzler HR, Armeli S, Tennen H, et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol. 2011;31:22–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171:445–52.

    Article  PubMed  PubMed Central  Google Scholar 

  163. Krebs MO, Guillin O, Bourdell MC, et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry. 2000;5:558–62.

    Article  CAS  PubMed  Google Scholar 

  164. Krebs MO, Sautel F, Bourdel MC, et al. Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol Psychiatry. 1998;3:337–41.

    Article  CAS  PubMed  Google Scholar 

  165. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734–9.

    Article  CAS  PubMed  Google Scholar 

  166. Kwon JS, Kim E, Kang D-H, et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol. 2008;18:897–907.

    Article  CAS  PubMed  Google Scholar 

  167. Labbe A, Liu A, Atherton J, et al. Refining psychiatric phenotypes for response to treatment: contribution of LPHN3 in ADHD. Am J Med Genet B Neuropsychiatr Genet. 2012;159B:776–85.

    Article  PubMed  CAS  Google Scholar 

  168. Lahdelma L, Ahokas A, Andersson LC, et al. Association between HLA-A1 allele and schizophrenia gene(s) in patients refractory to conventional neuroleptics but responsive to clozapine medication. Tissue Antigens. 2008;51:200–3.

    Article  Google Scholar 

  169. Lane H-Y, Chang Y-C, Chiu C-C, et al. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry. 2002;159:1593–5.

    Article  PubMed  Google Scholar 

  170. Lane H-Y, Hsu S-K, Liu Y-C, et al. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol. 2005;25:6–11.

    Article  CAS  PubMed  Google Scholar 

  171. Lane H-Y, Lee C-C, Chang Y-C, et al. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol. 2004a;7:461–70.

    Article  CAS  PubMed  Google Scholar 

  172. Lane H-Y, Lin C-C, Huang C-H, et al. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr Res. 2004b;67:63–70.

    Article  PubMed  Google Scholar 

  173. Lane H-Y, Liu Y-C, Huang C-L, et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J Clin Psychopharmacol. 2008;28:64–8.

    Article  CAS  PubMed  Google Scholar 

  174. Langley K, Turic D, Peirce TR, et al. No support for association between the dopamine transporter (DAT1) gene and ADHD. Am J Med Genet B Neuropsychiatr Genet. 2005;139B:7–10.

    Article  CAS  PubMed  Google Scholar 

  175. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry. 2009;14:804–19.

    Article  CAS  PubMed  Google Scholar 

  176. Lawford BR, Young RM, Noble EP, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet. 2000;96:592–8.

    Article  CAS  PubMed  Google Scholar 

  177. Lawford BR, Young RM, Rowell JA, et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med. 1995;1:337–41.

    Article  CAS  PubMed  Google Scholar 

  178. Lee HJ, Cha JH, Ham BJ, et al. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J. 2004;4:29–33.

    Article  CAS  PubMed  Google Scholar 

  179. Lee H-Y, Kim Y-K. Catechol-O-methyltransferase Val158Met polymorphism affects therapeutic response to mood stabilizer in symptomatic manic patients. Psychiatry Res. 2010;175:63–6.

    Article  CAS  PubMed  Google Scholar 

  180. Lee SH, Kim SW, Lee MG, et al. Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD. Psychiatry Res. 2011;186:338–44.

    Article  CAS  PubMed  Google Scholar 

  181. Lee S-Y, Chen S-L, Chang Y-H, et al. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Affect Disord. 2012;138:295–300.

    Article  CAS  PubMed  Google Scholar 

  182. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response – an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry. 2008;63:1103–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. Lett TA, Walter H, Brandl EJ. Pharmacogenetics and imaging-pharmacogenetics of antidepressant response: towards translational strategies. CNS Drugs. 2016;30:1169–89.

    Article  CAS  PubMed  Google Scholar 

  184. Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology. 2010;35:2143–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Licinio J, O’Kirwan F, Irizarry K, et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry. 2004;9:1075–82.

    Article  CAS  PubMed  Google Scholar 

  186. Lin E, Chen PS, Chang HH, et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33:1167–72.

    Article  CAS  Google Scholar 

  187. Lin E, Lane H-Y. Genome-wide association studies in pharmacogenomics of antidepressants. Pharmacogenomics. 2015;16:555–66.

    Article  CAS  PubMed  Google Scholar 

  188. Lin J-Y, Jiang M-Y, Kan Z-M, Chu Y. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014;168:430–8.

    Article  CAS  PubMed  Google Scholar 

  189. Lit L, Sharp FR, Bertoglio K, et al. Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. Pharmacogenomics J. 2012;12:368–71.

    Article  CAS  PubMed  Google Scholar 

  190. Liu B-C, Zhang J, Wang L, et al. HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients. Pharmacogenomics. 2010;11:685–92.

    Article  CAS  PubMed  Google Scholar 

  191. Lohoff FW, Aquino TD, Narasimhan S, et al. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013a;13:21–6.

    Article  CAS  PubMed  Google Scholar 

  192. Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013b;13:464–9.

    Article  CAS  PubMed  Google Scholar 

  193. Lonsdorf TB, Rück C, Bergström J, et al. The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry. 2010;10:99.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  194. Lopez de Lara C, Jaitovich-Groisman I, Cruceanu C, et al. Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses. Int J Neuropsychopharmacol. 2010;13:1397–410.

    Article  PubMed  CAS  Google Scholar 

  195. Løvlie R, Berle JO, Stordal E, Steen VM. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet. 2001;11:41–3.

    Article  PubMed  Google Scholar 

  196. Lucae S, Ising M, Horstmann S, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol. 2010;20:65–8.

    Article  CAS  PubMed  Google Scholar 

  197. Magliulo L, Dahl M-L, Lombardi G, et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol. 2011;67:47–54.

    Article  CAS  PubMed  Google Scholar 

  198. Mamdani F, Alda M, Grof P, et al. Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:500–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  199. Mancama D, Arranz MJ, Munro J, et al. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett. 2002;333:207–11.

    Article  CAS  PubMed  Google Scholar 

  200. Manchia M, Adli M, Akula N, et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a consortium on lithium genetics (ConLiGen) report. PLoS One. 2013;8:e65636.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  201. Manchia M, Congiu D, Squassina A, et al. No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Res. 2009a;169:164–6.

    Article  CAS  PubMed  Google Scholar 

  202. Manchia M, Squassina A, Congiu D, et al. Interacting genes in lithium prophylaxis: preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neurosci Lett. 2009b;467:67–71.

    Article  CAS  PubMed  Google Scholar 

  203. Mandelli L, Emiliani R, Porcelli S, et al. Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. Hum Psychopharmacol. 2014;29:388–91.

    Article  CAS  PubMed  Google Scholar 

  204. Manji HK, Lenox RH. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manicdepressive illness. Biol Psychiatry. 1999;46:1328–51.

    Article  CAS  PubMed  Google Scholar 

  205. Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998;19:123–32.

    Article  CAS  PubMed  Google Scholar 

  206. Masui T, Hashimoto R, Kusumi I, et al. A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:204–8.

    Article  CAS  Google Scholar 

  207. Masui T, Hashimoto R, Kusumi I, et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol. 2006;9:83–8.

    Article  CAS  PubMed  Google Scholar 

  208. Matsumoto Y, Fabbri C, Pellegrini S, et al. Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder. Mol Diagn Ther. 2014;18:567–77.

    Article  CAS  PubMed  Google Scholar 

  209. McCarthy MJ, Nievergelt CM, Shekhtman T, et al. Functional genetic variation in the Rev-Erbα pathway and lithium response in the treatment of bipolar disorder. Genes Brain Behav. 2011;10:852–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry. 2011a;16:76–85.

    Article  CAS  PubMed  Google Scholar 

  211. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology. 2011b;36:616–26.

    Article  CAS  PubMed  Google Scholar 

  212. McCracken JT, Badashova KK, Posey DJ, et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J. 2014;14:295–302.

    Article  CAS  PubMed  Google Scholar 

  213. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–21.

    Article  CAS  PubMed  Google Scholar 

  214. McGough JJ, McCracken JT, Loo SK, et al. A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1155–64.

    Article  PubMed  PubMed Central  Google Scholar 

  215. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  216. Méary A, Brousse G, Jamain S, et al. Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:491–4.

    Article  PubMed  CAS  Google Scholar 

  217. Meged S, Stein D, Sitrota P, et al. Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in Jewish Israeli schizophrenic patients. Int Clin Psychopharmacol. 1999;14:305–12.

    Article  CAS  PubMed  Google Scholar 

  218. Michelon L, Meira-Lima I, Cordeiro Q, et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and retrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett. 2006;403:288–93.

    Article  CAS  PubMed  Google Scholar 

  219. Mick E, Biederman J, Spencer T, et al. Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:890–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  220. Milanesi E, Bonvicini C, Congiu C, et al. The role of GRIK4 gene in treatment-resistant depression. Genet Res (Camb). 2015;97:e14.

    Article  CAS  Google Scholar 

  221. Mill J, Asherson P, Browes C, et al. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet. 2002;114:975–9.

    Article  PubMed  Google Scholar 

  222. Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:341–51.

    Article  CAS  PubMed  Google Scholar 

  223. Murphy GM, Sarginson JE, Ryan HS, et al. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenet Genomics. 2013;23:301–13.

    Article  CAS  PubMed  Google Scholar 

  224. Mushtaq D, Ali A, Margoob MA, et al. Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder. J Affect Disord. 2012;136:955–62.

    Article  CAS  PubMed  Google Scholar 

  225. Myung W, Lim S-W, Kim S, et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology. 2013;225:283–90.

    Article  CAS  PubMed  Google Scholar 

  226. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:183–94.

    Article  CAS  Google Scholar 

  227. Noordam R, Direk N, Sitlani CM, et al. Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study. J Psychiatr Res. 2015;62:31–7.

    Article  PubMed  Google Scholar 

  228. Nurmi EL, Spilman SL, Whelan F, et al. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry. 2013;3:e274.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  229. Ooteman W, Naassila M, Koeter MWJ, et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009;14:328–37.

    Article  CAS  PubMed  Google Scholar 

  230. Oslin DW. Prospective study of the Asn40Asp SNP as a moderator of naltrexone treatment of alcohol dependence. Oral presentation at the annual meeting of the Research Society on Alcoholism, Bellevue, WA, 21–25 June 2014.

    Google Scholar 

  231. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546–52.

    Article  CAS  PubMed  Google Scholar 

  232. Owley T, Brune CW, Salt J, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 2010;3:1–7.

    PubMed  PubMed Central  Google Scholar 

  233. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164:1181–8.

    Article  PubMed  Google Scholar 

  234. Pae C-U, Chiesa A, Porcelli S, et al. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology. 2012;65:1–11.

    Article  CAS  PubMed  Google Scholar 

  235. Papiol S, Arias B, Gastó C, et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104:83–90.

    Article  CAS  PubMed  Google Scholar 

  236. Pasini A, Sinibaldi L, Paloscia C, et al. Neurocognitive effects of methylphenidate on ADHD children with different DAT genotypes: a longitudinal open label trial. Eur J Paediatr Neurol. 2013;17:407–14.

    Article  CAS  PubMed  Google Scholar 

  237. Perkins KA, Lerman C, Coddington S, et al. Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers. Behav Pharmacol. 2008a;19:630–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  238. Perkins KA, Lerman C, Grottenthaler A, et al. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol. 2008b;19:641–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  239. Perlis RH, Adams DH, Fijal B, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry. 2010a;71:599–605.

    Article  CAS  PubMed  Google Scholar 

  240. Perlis RH, Fijal B, Dharia S, et al. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry. 2010b;67:1110–3.

    Article  CAS  PubMed  Google Scholar 

  241. Perlis RH, Fijal B, Dharia S, Houston JP. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J. 2013;13:280–5.

    Article  CAS  PubMed  Google Scholar 

  242. Perlis RH, Smoller JW, Ferreira MAR, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry. 2009;166:718–25.

    Article  PubMed  PubMed Central  Google Scholar 

  243. Perna G, Favaron E, Di Bella D, et al. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology. 2005;30:2230–5.

    Article  CAS  PubMed  Google Scholar 

  244. Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics. 2011;12:365–77.

    Article  PubMed  Google Scholar 

  245. Pescosolido MF, Yang U, Sabbagh M, Morrow EM. Lighting a path: genetic studies pinpoint neurodevelopmental mechanisms in autism and related disorders. Dialogues Clin Neurosci. 2012;14:239–52.

    PubMed  PubMed Central  Google Scholar 

  246. Peters EJ, Slager SL, Jenkins GD, et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics. 2009;19:1–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  247. Peters EJ, Slager SL, McGrath PJ, et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry. 2004;9:879–89.

    Article  CAS  PubMed  Google Scholar 

  248. Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73:761–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  249. Polanczyk G, Zeni C, Genro JP, et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64:218–24.

    Article  CAS  PubMed  Google Scholar 

  250. Poland RE, Lesser IM, Wan Y-JY, et al. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. Life Sci. 2013;92:967–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  251. Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot study. Pharmacogenomics. 2006;7:159–66.

    Article  CAS  PubMed  Google Scholar 

  252. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22:239–58.

    Article  CAS  PubMed  Google Scholar 

  253. Potkin SG, Basile VS, Jin Y, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry. 2003;8:109–13.

    Article  CAS  PubMed  Google Scholar 

  254. Powell TR, Schalkwyk LC, Heffernan AL, et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur Neuropsychopharmacol. 2013;23:1105–14.

    Article  CAS  PubMed  Google Scholar 

  255. Proft F, Kopf J, Olmes D, et al. SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome. Pharmacopsychiatry. 2014;47:245–50.

    Article  CAS  PubMed  Google Scholar 

  256. Pu M, Zhang Z, Xu Z, et al. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. Pharmacogenomics. 2013;14:277–88.

    Article  CAS  PubMed  Google Scholar 

  257. Purper-Ouakil D, Wohl M, Orejarena S, et al. Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1425–30.

    Article  CAS  PubMed  Google Scholar 

  258. Qin H, Samuels JF, Wang Y, et al. Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol Psychiatry. 2016;21:270–6.

    Article  CAS  PubMed  Google Scholar 

  259. Rahman MA, Ashton AC, Meunier FA, et al. Norepinephrine exocytosis stimulated by alpha-latrotoxin requires both external and stored Ca2+ and is mediated by latrophilin, G proteins and phospholipase C. Philos Trans R Soc Lond Ser B Biol Sci. 1999;354:379–86.

    Article  CAS  Google Scholar 

  260. Rao PA, Pickar D, Gejman PV, et al. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry. 1994;51:912–7.

    Article  CAS  PubMed  Google Scholar 

  261. Ray LA, Miranda R, MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17:122–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  262. Reif A, Richter J, Straube B, et al. MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. Mol Psychiatry. 2014;19:122–8.

    Article  CAS  PubMed  Google Scholar 

  263. Ribasés M, Ramos-Quiroga JA, Sánchez-Mora C, et al. Contribution of LPHN3 to the genetic susceptibility to ADHD in adulthood: a replication study. Genes Brain Behav. 2011;10:149–57.

    Article  PubMed  CAS  Google Scholar 

  264. Rietschel M, Naber D, Oberländer H, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology. 1996;15:491–6.

    Article  CAS  PubMed  Google Scholar 

  265. Risner ME, Saunders AM, Altman JFB, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. 2006;6:246–54.

    Article  CAS  PubMed  Google Scholar 

  266. Robinson JD, Lam CY, Minnix JA, et al. The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Pharmacogenomics J. 2007;7:266–74.

    Article  CAS  PubMed  Google Scholar 

  267. Roman T, Szobot C, Martins S, et al. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics. 2002;12:497–9.

    Article  CAS  PubMed  Google Scholar 

  268. Roses AD. The medical and economic roles of pipeline pharmacogenetics: Alzheimer’s disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Neuropsychopharmacology. 2009;34:6–17.

    Article  CAS  PubMed  Google Scholar 

  269. Roses AD, Saunders AM, Huang Y, et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer’s disease). Pharmacogenomics J. 2007;7:10–28.

    Article  CAS  PubMed  Google Scholar 

  270. Rotberg B, Kronenberg S, Carmel M, et al. Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. J Child Adolesc Psychopharmacol. 2013;23:117–22.

    Article  CAS  PubMed  Google Scholar 

  271. Rybakowski JK, Czerski P, Dmitrzak-Weglarz M, et al. Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy. J Psychopharmacol (Oxford). 2012;26:368–73.

    Article  CAS  Google Scholar 

  272. Rybakowski JK, Dmitrzak-Weglarz M, Suwalska A, et al. Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder. Pharmacopsychiatry. 2009;42:20–2.

    Article  CAS  PubMed  Google Scholar 

  273. Rybakowski JK, Suwalska A, Czerski PM, et al. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep. 2005a;57:124–7.

    CAS  PubMed  Google Scholar 

  274. Rybakowski JK, Suwalska A, Skibinska M, et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry. 2005b;38:166–70.

    Article  CAS  PubMed  Google Scholar 

  275. Rybakowski JK, Suwalska A, Skibinska M, et al. Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:820–3.

    Article  CAS  PubMed  Google Scholar 

  276. Sahraian S, Babashams M, Reza-Soltani P, et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness in Iranian patients with major depressive disorder. Iran J Psychiatry. 2013;8:86–91.

    PubMed  PubMed Central  Google Scholar 

  277. Sarginson JE, Lazzeroni LC, Ryan HS, et al. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:554–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  278. Saung WT, Narasimhan S, Lohoff FW. Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder. Hum Psychopharmacol. 2014;29:316–21.

    Article  CAS  PubMed  Google Scholar 

  279. Schäfer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry. 2001;158:802–4.

    Article  PubMed  Google Scholar 

  280. Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. Eur Neuropsychopharmacol. 1999;10:17–20.

    Article  CAS  PubMed  Google Scholar 

  281. Schulze TG, Alda M, Adli M, et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology. 2010;62:72–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  282. Seripa D, Pilotto A, Paroni G, et al. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. J Psychopharmacol (Oxford). 2015;29:623–33.

    Article  CAS  Google Scholar 

  283. Serretti A, Artioli P, Lorenzi C, et al. The C(−1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004a;7:453–60.

    Article  CAS  PubMed  Google Scholar 

  284. Serretti A, Chiesa A, Crisafulli C, et al. Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. Neuropsychobiology. 2012;65:70–5.

    Article  CAS  PubMed  Google Scholar 

  285. Serretti A, Cusin C, Rossini D, et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet. 2004b;129B:36–40.

    Article  PubMed  Google Scholar 

  286. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247–57.

    Article  CAS  PubMed  Google Scholar 

  287. Serretti A, Lilli R, Lorenzi C, et al. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res. 1999a;33:371–7.

    Article  CAS  PubMed  Google Scholar 

  288. Serretti A, Lilli R, Lorenzi C, et al. Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res. 1999b;87:7–19.

    Article  CAS  PubMed  Google Scholar 

  289. Serretti A, Lilli R, Lorenzi C, et al. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int J Neuropsychopharmacol. 1998;1:125–9.

    Article  PubMed  Google Scholar 

  290. Serretti A, Lorenzi C, Cusin C, et al. SSRIs antidepressant activity is influenced by G beta 3 variants. Eur Neuropsychopharmacol. 2003;13:117–22.

    Article  CAS  PubMed  Google Scholar 

  291. Serretti A, Lorenzi C, Lilli R, et al. Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. Am J Med Genet. 2002;114:370–9.

    Article  PubMed  Google Scholar 

  292. Serretti A, Lorenzi C, Lilli R, Smeraldi E. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res. 2000;34:89–98.

    Article  CAS  PubMed  Google Scholar 

  293. Serretti A, Malitas PN, Mandelli L, et al. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J. 2004c;4:267–73.

    Article  CAS  PubMed  Google Scholar 

  294. Serretti A, Zanardi R, Cusin C, et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol. 2001a;11:375–80.

    Article  CAS  PubMed  Google Scholar 

  295. Serretti A, Zanardi R, Rossini D, et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry. 2001b;6:586–92.

    Article  CAS  PubMed  Google Scholar 

  296. Severino G, Squassina A, Costa M, et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013;14:655–74.

    Article  CAS  PubMed  Google Scholar 

  297. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet. 1993;341:116.

    Article  CAS  PubMed  Google Scholar 

  298. Shaikh S, Collier DA, Sham PC, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet. 1996;97:714–9.

    Article  CAS  PubMed  Google Scholar 

  299. Shaikh S, Makoff A, Collier D, Kerwin R. Dopamine D4 receptors. CNS Drugs. 1997;8:1–11.

    Article  CAS  Google Scholar 

  300. Shen Y-C, Chen S-F, Chen C-H, et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res. 2009;43:600–6.

    Article  PubMed  Google Scholar 

  301. Sherman WR, Gish BG, Honchar MP, Munsell LY. Effects of lithium on phosphoinositide metabolism in vivo. Fed Proc. 1986;45:2639–46.

    CAS  PubMed  Google Scholar 

  302. Shiroma PR, Drews MS, Geske JR, Mrazek DA. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry. 2014;22:1140–8.

    Article  PubMed  Google Scholar 

  303. Shorter D, Nielsen DA, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. Eur Neuropsychopharmacol. 2013;23:1401–7.

    Article  CAS  PubMed  Google Scholar 

  304. Silberberg G, Levit A, Collier D, et al. Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet Genomics. 2008;18:403–12.

    Article  CAS  PubMed  Google Scholar 

  305. Smits KM, Smits LJM, Peeters FPML, et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet. 2008;18:184–90.

    Article  PubMed  Google Scholar 

  306. Sodhi MS, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport. 1995;7:169–72.

    Article  CAS  PubMed  Google Scholar 

  307. Souza RP, de Luca V, Meltzer HY, et al. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol. 2010a;13:793–8.

    Article  CAS  PubMed  Google Scholar 

  308. Souza RP, Romano-Silva MA, Lieberman JA, et al. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. J Psychiatr Res. 2010b;44:700–6.

    Article  PubMed  Google Scholar 

  309. Spellicy CJ, Kosten TR, Hamon SC, et al. ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenet Genomics. 2013;23:333–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  310. Squassina A, Congiu D, Manconi F, et al. The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacol Res. 2008;57:369–73.

    Article  CAS  PubMed  Google Scholar 

  311. Squassina A, Manchia M, Borg J, et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics. 2011;12:1559–69.

    Article  CAS  PubMed  Google Scholar 

  312. Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology. 2002;162:18–23.

    Article  CAS  PubMed  Google Scholar 

  313. Staeker J, Leucht S, Laika B, Steimer W. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet Test Mol Biomarkers. 2014;18:20–31.

    Article  CAS  PubMed  Google Scholar 

  314. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6:1664–8.

    Article  CAS  PubMed  Google Scholar 

  315. Stamm TJ, Rampp C, Wiethoff K, et al. The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. J Psychopharmacol (Oxford). 2016;30:40–7.

    Article  CAS  Google Scholar 

  316. Stapleton JA, Sutherland G, O’Gara C, et al. Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy. Pharmacogenet Genomics. 2011;21:447–53.

    Article  CAS  PubMed  Google Scholar 

  317. Steen VM, Løvlie R, Osher Y, et al. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics. 1998;8:259–68.

    CAS  PubMed  Google Scholar 

  318. Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005;30:1374–82.

    Article  CAS  PubMed  Google Scholar 

  319. Stein MB, Keshaviah A, Haddad SA, et al. Influence of RGS2 on sertraline treatment for social anxiety disorder. Neuropsychopharmacology. 2014;39:1340–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  320. Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology. 2006;187:68–72.

    Article  CAS  PubMed  Google Scholar 

  321. Stigler KA, Diener JT, Kohn AE, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol. 2009;19:265–74.

    Article  PubMed  PubMed Central  Google Scholar 

  322. Sugie Y, Sugie H, Fukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J Autism Dev Disord. 2005;35:377–85.

    Article  PubMed  Google Scholar 

  323. Szczepankiewicz A, Rybakowski JK, Suwalska A, et al. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry. 2006;7:158–61.

    Article  PubMed  Google Scholar 

  324. Szczepankiewicz A, Skibińska M, Suwalska A, et al. No association of three GRIN2B polymorphisms with lithium response in bipolar patients. Pharmacol Rep. 2009a;61:448–52.

    Article  CAS  PubMed  Google Scholar 

  325. Szczepankiewicz A, Skibinska M, Suwalska A, et al. The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients. Hum Psychopharmacol. 2009b;24:287–91.

    Article  CAS  PubMed  Google Scholar 

  326. Szekeres G, Kéri S, Juhász A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2004;124B:1–5.

    Article  PubMed  Google Scholar 

  327. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010;68:536–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  328. Thakur GA, Grizenko N, Sengupta SM, et al. The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioural response to methylphenidate in children with ADHD. BMC Psychiatry. 2010;10:50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  329. Thomas P, Srivastava V, Singh A, et al. Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry Res. 2008;161:275–83.

    Article  CAS  PubMed  Google Scholar 

  330. Trautmann S, Richter J, Muehlhan M, et al. Does prior traumatization affect the treatment outcome of CBT for panic disorder? The potential role of the MAOA gene and depression symptoms. Eur Arch Psychiatry Clin Neurosci. 2017;15.

    Google Scholar 

  331. Tsai S-J, Hong C-J, Chen T-J, Yu YW-Y. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:1097–8.

    Article  CAS  PubMed  Google Scholar 

  332. Tsai SJ, Wang YC, Yu Younger WY, et al. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res. 2001;49:53–8.

    Article  CAS  PubMed  Google Scholar 

  333. Turecki G, Grof P, Cavazzoni P, et al. MAOA: association and linkage studies with lithium responsive bipolar disorder. Psychiatr Genet. 1999a;9:13–6.

    Article  CAS  PubMed  Google Scholar 

  334. Turecki G, Grof P, Cavazzoni P, et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry. 1998;3:534–8.

    Article  CAS  PubMed  Google Scholar 

  335. Turecki G, Grof P, Cavazzoni P, et al. Lithium responsive bipolar disorder, unilineality, and chromosome 18: a linkage study. Am J Med Genet. 1999b;88:411–5.

    Article  CAS  PubMed  Google Scholar 

  336. Turecki G, Grof P, Grof E, et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry. 2001;6:570–8.

    Article  CAS  PubMed  Google Scholar 

  337. van der Meulen EM, Bakker SC, Pauls DL, et al. High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J Child Psychol Psychiatry. 2005;46:1074–80.

    Article  PubMed  Google Scholar 

  338. Villafuerte SM, Vallabhaneni K, Sliwerska E, et al. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet. 2009;19:281–91.

    Article  PubMed  PubMed Central  Google Scholar 

  339. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14:1024–31.

    Article  CAS  PubMed  Google Scholar 

  340. Wang L, Fang C, Zhang A, et al. The – 1019 C/G polymorphism of the 5-HT(1) A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol (Oxford). 2008;22:904–9.

    Article  CAS  PubMed  Google Scholar 

  341. Wang L, Yu L, He G, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett. 2007;414:1–4.

    Article  CAS  PubMed  Google Scholar 

  342. Wang Z, Fan J, Gao K, et al. Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I disorder. J Mol Neurosci. 2013;50:305–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  343. Wang Z, Li Z, Chen J, et al. Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population. Genes Brain Behav. 2012;11:524–8.

    Article  CAS  PubMed  Google Scholar 

  344. Wei Z, Wang L, Xuan J, et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33:547–51.

    Article  CAS  Google Scholar 

  345. Wilkie MJV, Smith D, Reid IC, et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics. 2007;17:207–15.

    Article  CAS  PubMed  Google Scholar 

  346. Wilkie MJV, Smith G, Day RK, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009;9:61–70.

    Article  CAS  PubMed  Google Scholar 

  347. Williams K, Brignell A, Randall M, et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013;8:CD004677.

    Google Scholar 

  348. Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol. 2010;12:529–38.

    Article  PubMed  Google Scholar 

  349. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry. 1999;38:1474–7.

    Article  CAS  PubMed  Google Scholar 

  350. Won E-S, Chang H-S, Lee H-Y, et al. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology. 2012;66:221–9.

    Article  CAS  PubMed  Google Scholar 

  351. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res. 2007;90:86–96.

    Article  PubMed  Google Scholar 

  352. Wu G-S, Luo H-R, Dong C, et al. Sequence polymorphisms of MC1R gene and their association with depression and antidepressant response. Psychiatr Genet. 2011;21:14–8.

    Article  CAS  PubMed  Google Scholar 

  353. Wu S, Xing Q, Gao R, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005;376:1–4.

    Article  CAS  PubMed  Google Scholar 

  354. Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics. 2006;7:987–93.

    Article  CAS  PubMed  Google Scholar 

  355. Xing Q, Qian X, Li H, et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol. 2007;10:631–7.

    Article  CAS  PubMed  Google Scholar 

  356. Xu M, Xing Q, Li S, et al. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34:1026–32.

    Article  CAS  Google Scholar 

  357. Xu M-Q, St Clair D, Feng G-Y, et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics. 2008;18:449–57.

    Article  CAS  PubMed  Google Scholar 

  358. Xu Z, Zhang Z, Shi Y, et al. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol (Oxford). 2012;26:349–59.

    Article  CAS  Google Scholar 

  359. Xuan J, Zhao X, He G, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology. 2008;33:305–11.

    Article  CAS  PubMed  Google Scholar 

  360. Yamanouchi Y, Iwata N, Suzuki T, et al. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 2003;3:356–61.

    Article  CAS  PubMed  Google Scholar 

  361. Yan T, Wang L, Kuang W, et al. Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis. Asia Pac Psychiatry. 2014;6:241–51.

    Article  PubMed  Google Scholar 

  362. Yang L, Qian Q, Liu L, et al. Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transm. 2013;120:1127–33.

    Article  CAS  PubMed  Google Scholar 

  363. Yasui-Furukori N, Saito M, Nakagami T, et al. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:286–91.

    Article  CAS  Google Scholar 

  364. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1–44.

    Article  CAS  PubMed  Google Scholar 

  365. Yehuda R, Pratchett LC, Elmes MW, et al. Glucocorticoid-related predictors and correlates of post-traumatic stress disorder treatment response in combat veterans. Interface Focus. 2014;4:20140048.

    Article  PubMed  PubMed Central  Google Scholar 

  366. Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord. 2010;123:308–11.

    Article  CAS  PubMed  Google Scholar 

  367. Yin L, Zhang YY, Zhang X, et al. TPH, SLC6A2, SLC6A3, DRD2 and DRD4 polymorphisms and neuroendocrine factors predict SSRIs treatment outcome in the Chinese population with major depression. Pharmacopsychiatry. 2015;48:95–103.

    Article  CAS  PubMed  Google Scholar 

  368. Yu YW, Tsai SJ, Lin CH, et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport. 1999;10:1231–3.

    Article  CAS  PubMed  Google Scholar 

  369. Yu YW, Tsai SJ, Yang KH, et al. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology. 2001;43:79–82.

    Article  CAS  PubMed  Google Scholar 

  370. Yu YW-Y, Tsai S-J, Liou Y-J, et al. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol. 2006;16:498–503.

    Article  CAS  PubMed  Google Scholar 

  371. Yudkin P, Munafò M, Hey K, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ. 2004;328:989–90.

    Article  PubMed  PubMed Central  Google Scholar 

  372. Zai G, Brandl EJ, Müller DJ, et al. Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics. 2014;15:1147–57.

    Article  CAS  PubMed  Google Scholar 

  373. Zalsman G, Frisch A, Lev-Ran S, et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol. 2003;13:183–5.

    Article  CAS  PubMed  Google Scholar 

  374. Zanardi R, Serretti A, Rossini D, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 2001;50:323–30.

    Article  CAS  PubMed  Google Scholar 

  375. Zeni CP, Guimarães AP, Polanczyk GV, et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:391–4.

    Article  PubMed  Google Scholar 

  376. Zhao A-L, Zhao J-P, Zhang Y-H, et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005;115:1539–47.

    Article  CAS  PubMed  Google Scholar 

  377. Zhao X, Huang Y, Li J, et al. Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: a meta-analysis. Int Clin Psychopharmacol. 2012;27:314–20.

    Article  PubMed  Google Scholar 

  378. Zill P, Baghai TC, Zwanzger P, et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport. 2000;11:1893–7.

    Article  CAS  PubMed  Google Scholar 

  379. Zou Y-F, Wang F, Feng X-L, et al. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci Lett. 2010;484:56–61.

    Article  CAS  PubMed  Google Scholar 

  380. Zuo L, Luo X, Krystal JH, et al. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics. 2009;19:437–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK

    Eduard Maron, Chen-Chia Lan & David Nutt

  2. Department of Psychiatry, University of Tartu, Tartu, Estonia

    Eduard Maron

  3. Department of Psychiatry, North Estonia Medical Centre, Tallinn, Estonia

    Eduard Maron

  4. Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan

    Chen-Chia Lan

Authors
  1. Eduard Maron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chen-Chia Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Nutt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduard Maron .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea (Republic of)

    Yong-Ku Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Maron, E., Lan, CC., Nutt, D. (2019). Genetic Factors Underlying Treatment Resistance in Psychiatry. In: Kim, YK. (eds) Treatment Resistance in Psychiatry. Springer, Singapore. https://doi.org/10.1007/978-981-10-4358-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-4358-1_3

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-4357-4

  • Online ISBN: 978-981-10-4358-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation